Another trispecific developed by the Swiss company Numab, the scFv-based NM21-1480 (scFv3, Figure 1e and Table 1) is not a classical T-/NK cell engager, but rather activates immune cells by simultaneous binding of PD-L1, 4-1BB, and HSA (the latter to prolong the half-life) and is currently in phase 1/2 testing against advanced cancers (NCT04442126). Here, CD274 is linked to cancer.